Clinical Trial Search

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Mortality — 0; 0 percentage of mortality

Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Change in Peak Aerobic Capacity — 17.1; 16.8; 17.9; 15.9 ml/kg/min

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04

Primary: Peak Oxygen Consumption — 3.07 ml/min/kg

Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05

Primary: Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients…

Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg

Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2

Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57

Primary: Composite Global Cognitive Function — .15; .02 Z-score

Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD

Primary: Change From Baseline in eGFR at 6 Months (Patient-specific) — -2.35; -4.24 mL/min/1.73m^2

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale

Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257

Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute

Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045

Primary: Change in Urine Albumin Excretion — -21; -5 percent difference

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1 Participants